Abaloparatide for treating osteoporosis after menopause (TA991)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 August 2024
Romosozumab for treating severe osteoporosis (TA791)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 May 2022
Bisphosphonates for treating osteoporosis (TA464)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 8 July 2019Published: 9 August 2017
Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 7 February 2018Published: 27 October 2008
Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 7 February 2018Published: 27 October 2008
Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures (TA279)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 April 2013
Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 October 2010
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
TVB-009 (denosumab biosimilar) for treating postmenopausal osteoporosis in people aged 60 to 90 TS ID 11807Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC